Cargando…

Hypoallergenicity assessment of an extensively hydrolyzed whey‐protein formula in cow’s milk allergic infants

BACKGROUND:  Extensively hydrolyzed formulas are recommended for the dietary management of infants with cow's milk allergy (CMA). OBJECTIVES: Hypoallergenicity, growth, and gastrointestinal (GI) tolerability of a new extensively hydrolyzed whey‐protein formula (eHWF) in CMA children were assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Dahdah, Lamia, Roelofs, Mieke, Knipping, Karen, de Vries, Esther, Rijnierse, Anneke, Garssen, Johan, Brand, Paul L. P., Fiocchi, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542408/
https://www.ncbi.nlm.nih.gov/pubmed/35754130
http://dx.doi.org/10.1111/pai.13814
_version_ 1784804142723629056
author Dahdah, Lamia
Roelofs, Mieke
Knipping, Karen
de Vries, Esther
Rijnierse, Anneke
Garssen, Johan
Brand, Paul L. P.
Fiocchi, Alessandro
author_facet Dahdah, Lamia
Roelofs, Mieke
Knipping, Karen
de Vries, Esther
Rijnierse, Anneke
Garssen, Johan
Brand, Paul L. P.
Fiocchi, Alessandro
author_sort Dahdah, Lamia
collection PubMed
description BACKGROUND:  Extensively hydrolyzed formulas are recommended for the dietary management of infants with cow's milk allergy (CMA). OBJECTIVES: Hypoallergenicity, growth, and gastrointestinal (GI) tolerability of a new extensively hydrolyzed whey‐protein formula (eHWF) in CMA children were assessed. METHODS: In this prospective, randomized, international, multi‐center study (Trial NL3889), 34 children with confirmed CMA (74% IgE‐mediated) underwent a double‐blind, placebo‐controlled food challenge (DBPCFC) with an eHWF developed with non‐porcine enzymes, supplemented with prebiotic short‐chain galacto‐ and long‐chain fructo‐oligosaccharides (0.8 g/L, ratio 9:1), arachidonic acid (0.35/100 g), and docosahexaenoic acid (0.35/100 g). If tolerant to the eHWF, children participated in a 7‐day open food challenge with this eHWF. Anthropometrics and GI tolerability were assessed in an optional 16‐weeks follow‐up. RESULTS: Of the 34 children who started the DBPCFC with the eHWF, 25 subjects (19 boys, mean age: 61 weeks, 18 with IgE‐mediated CMA) completed the DBPCFC and 7‐day open challenge without major protocol deviations and tested negative at both challenges. One child experienced a late moderate eczematous allergic reaction in the optional follow‐up period, indicating the need for close monitoring of subjects starting new formula. Weight and length gain followed the World Health Organization growth curves. Changes in frequency and consistency of stools upon test formula intake were transient. CONCLUSIONS: The newly developed eHWF is a suitable option in CMA treatment as all subjects tolerated the product. This result is in line with the international criteria for hypoallergenicity (American Academy of Pediatrics) that state that more than 90% of CMA children must tolerate the formula. Use of the formula is also associated with normal growth curves and GI tolerability. TRIAL REGISTRATION: Trial NL3889, https://www.trialregister.nl/trial/3889.
format Online
Article
Text
id pubmed-9542408
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95424082022-10-14 Hypoallergenicity assessment of an extensively hydrolyzed whey‐protein formula in cow’s milk allergic infants Dahdah, Lamia Roelofs, Mieke Knipping, Karen de Vries, Esther Rijnierse, Anneke Garssen, Johan Brand, Paul L. P. Fiocchi, Alessandro Pediatr Allergy Immunol Original Articles BACKGROUND:  Extensively hydrolyzed formulas are recommended for the dietary management of infants with cow's milk allergy (CMA). OBJECTIVES: Hypoallergenicity, growth, and gastrointestinal (GI) tolerability of a new extensively hydrolyzed whey‐protein formula (eHWF) in CMA children were assessed. METHODS: In this prospective, randomized, international, multi‐center study (Trial NL3889), 34 children with confirmed CMA (74% IgE‐mediated) underwent a double‐blind, placebo‐controlled food challenge (DBPCFC) with an eHWF developed with non‐porcine enzymes, supplemented with prebiotic short‐chain galacto‐ and long‐chain fructo‐oligosaccharides (0.8 g/L, ratio 9:1), arachidonic acid (0.35/100 g), and docosahexaenoic acid (0.35/100 g). If tolerant to the eHWF, children participated in a 7‐day open food challenge with this eHWF. Anthropometrics and GI tolerability were assessed in an optional 16‐weeks follow‐up. RESULTS: Of the 34 children who started the DBPCFC with the eHWF, 25 subjects (19 boys, mean age: 61 weeks, 18 with IgE‐mediated CMA) completed the DBPCFC and 7‐day open challenge without major protocol deviations and tested negative at both challenges. One child experienced a late moderate eczematous allergic reaction in the optional follow‐up period, indicating the need for close monitoring of subjects starting new formula. Weight and length gain followed the World Health Organization growth curves. Changes in frequency and consistency of stools upon test formula intake were transient. CONCLUSIONS: The newly developed eHWF is a suitable option in CMA treatment as all subjects tolerated the product. This result is in line with the international criteria for hypoallergenicity (American Academy of Pediatrics) that state that more than 90% of CMA children must tolerate the formula. Use of the formula is also associated with normal growth curves and GI tolerability. TRIAL REGISTRATION: Trial NL3889, https://www.trialregister.nl/trial/3889. John Wiley and Sons Inc. 2022-06-14 2022-06 /pmc/articles/PMC9542408/ /pubmed/35754130 http://dx.doi.org/10.1111/pai.13814 Text en © 2022 Nutricia Research B.V. Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Dahdah, Lamia
Roelofs, Mieke
Knipping, Karen
de Vries, Esther
Rijnierse, Anneke
Garssen, Johan
Brand, Paul L. P.
Fiocchi, Alessandro
Hypoallergenicity assessment of an extensively hydrolyzed whey‐protein formula in cow’s milk allergic infants
title Hypoallergenicity assessment of an extensively hydrolyzed whey‐protein formula in cow’s milk allergic infants
title_full Hypoallergenicity assessment of an extensively hydrolyzed whey‐protein formula in cow’s milk allergic infants
title_fullStr Hypoallergenicity assessment of an extensively hydrolyzed whey‐protein formula in cow’s milk allergic infants
title_full_unstemmed Hypoallergenicity assessment of an extensively hydrolyzed whey‐protein formula in cow’s milk allergic infants
title_short Hypoallergenicity assessment of an extensively hydrolyzed whey‐protein formula in cow’s milk allergic infants
title_sort hypoallergenicity assessment of an extensively hydrolyzed whey‐protein formula in cow’s milk allergic infants
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542408/
https://www.ncbi.nlm.nih.gov/pubmed/35754130
http://dx.doi.org/10.1111/pai.13814
work_keys_str_mv AT dahdahlamia hypoallergenicityassessmentofanextensivelyhydrolyzedwheyproteinformulaincowsmilkallergicinfants
AT roelofsmieke hypoallergenicityassessmentofanextensivelyhydrolyzedwheyproteinformulaincowsmilkallergicinfants
AT knippingkaren hypoallergenicityassessmentofanextensivelyhydrolyzedwheyproteinformulaincowsmilkallergicinfants
AT devriesesther hypoallergenicityassessmentofanextensivelyhydrolyzedwheyproteinformulaincowsmilkallergicinfants
AT rijnierseanneke hypoallergenicityassessmentofanextensivelyhydrolyzedwheyproteinformulaincowsmilkallergicinfants
AT garssenjohan hypoallergenicityassessmentofanextensivelyhydrolyzedwheyproteinformulaincowsmilkallergicinfants
AT brandpaullp hypoallergenicityassessmentofanextensivelyhydrolyzedwheyproteinformulaincowsmilkallergicinfants
AT fiocchialessandro hypoallergenicityassessmentofanextensivelyhydrolyzedwheyproteinformulaincowsmilkallergicinfants